Genetic Technologies Limited
GENE
$0.765
-$0.015-1.92%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.22M | 1.22M | 1.29M | 1.30M | 1.51M |
| Total Other Revenue | 360.40K | 359.60K | 297.90K | 299.40K | 279.80K |
| Total Revenue | 1.58M | 1.58M | 1.59M | 1.60M | 1.79M |
| Cost of Revenue | 660.30K | 658.90K | 572.30K | 575.10K | 730.60K |
| Gross Profit | 921.20K | 919.30K | 1.02M | 1.02M | 1.06M |
| SG&A Expenses | 1.94M | 1.94M | 1.89M | 1.90M | 1.75M |
| Depreciation & Amortization | 83.80K | 83.60K | 91.50K | 91.90K | 115.70K |
| Other Operating Expenses | 562.30K | 561.10K | 591.50K | 594.40K | 631.70K |
| Total Operating Expenses | 3.37M | 3.36M | 3.27M | 3.29M | 3.47M |
| Operating Income | -1.79M | -1.79M | -1.68M | -1.69M | -1.68M |
| Income Before Tax | -1.84M | -1.84M | -2.09M | -2.10M | -2.10M |
| Income Tax Expenses | -- | -- | -- | -- | -3.40K |
| Earnings from Continuing Operations | -1.84M | -1.84M | -2.09M | -2.10M | -2.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.84M | -1.84M | -2.09M | -2.10M | -2.10M |
| EBIT | -1.79M | -1.79M | -1.68M | -1.69M | -1.68M |
| EBITDA | -1.71M | -1.70M | -1.59M | -1.60M | -1.66M |
| EPS Basic | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 149.02M | 149.02M | 115.42M | 115.42M | 110.42M |
| Average Diluted Shares Outstanding | 149.02M | 149.02M | 115.42M | 115.42M | 110.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
